Pharmacy News Article

By a News Reporter-Staff News Editor at Clinical Oncology Week Research findings on Carcinomas are discussed in a new report. According to news reporting from Nagoya, Japan, by NewsRx journalists, researchers stated "To estimate the long-term clinical outcome of patients with recurrent clear cell carcinoma (RCCC) of the ovary in comparison with those with recurrent serous adenocarcinoma (RSAC). In this study, 113 patients with RCCC and 365 patients with RSAC were analyzed."

The news correspondents obtained a quote from the research by the authors from Aichi Cancer Center Hospital, "The pathological slides were evaluated under central pathological review. End points were the overall survival (OS), postrecurrence survival (PRS), and timing of death of mortality cases. The 5-year OS and PRS rates of patients with RCCC were 22.5 and 13.2%, respectively. In both OS and PRS, the prognosis of patients with RCCC was significantly poorer than that of the patients with RSAC (OS: P = 0.0007; PRS: P< 0.0001). Moreover, regardless of the status of the residual tumor (RT) at the initial surgery, the OS and PRS of the patients with RCCC were markedly shorter than those with RSAC (RT [-]: OS, P = 0.0005: PRS, P = 0.0002: RT [+]: OS, P< 0.0001: PRS, P<0.0001). In multivariable analysis, the histological type was a significantly poorer prognostic indicator for OS and PRS (OS [RCCC VS RSAC]: hazard ratio, 2.302: 95% confidence interval, 1.723-3.076; P< 0.0001: PRS [RCCC vs RSAC]; hazard ratio, 2.353: 95% confidence interval, 1.756-3.155; P< 0.0001). Even in the deceased patients (n = 350), the rate of patients with RCCC dying within 12 months of recurrence was higher than that of RSAC (RCCC, 67.8%; RSAC, 40.7%; [P < 0.0001]). The long-term clinical outcome of patients with RCCC was extremely poor."

According to the news reporters, the researchers concluded: "We confirmed that RCCC should be investigated as a different malignancy compared with RSAC."

For more information on this research see: Postrecurrent Oncologic Outcome of Patients With Ovarian Clear Cell Carcinoma. International Journal of Gynecological Cancer, 2012;22(5):801-806. International Journal of Gynecological Cancer can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA. (Lippincott Williams and Wilkins - www.lww.com; International Journal of Gynecological Cancer - journals.lww.com/ijgc/pages/default.aspx)

Our news journalists report that additional information may be obtained by contacting H. Kajiyama, Aichi Canc Center Hosp, Dept. of Gynecol, Nagoya, Aichi 464, Japan (see also Carcinomas).

Keywords for this news article include: Asia, Japan, Nagoya, Oncology

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC